Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells
US11357796B2 · kind B2 · utility
0Cited by
10References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 3, 2018 |
| Grant date | Jun 14, 2022 |
| Priority date | — |
| Expiry date | Jul 18, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of determining an effective dose of a T cell immunotherapy comprising polyfunctional T cells prior to administration to the patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.